- Home
- SANA vs ALVO Comparison
SANA vs ALVO Comparison
Compare SANA & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANA | ALVO |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SANA | ALVO |
|---|---|---|
| Price | $3.12 | $3.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $7.80 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.6M | 393.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $3.03 |
| 52 Week High | $6.55 | $11.85 |
Technical Indicators
Market Signals| Indicator | SANA | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 46.12 |
| Support Level | $3.03 | $3.10 |
| Resistance Level | $3.43 | $3.83 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 23.81 | 29.20 |
Price Performance
Historical ComparisonAbout SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.